Regeneron Pharmaceuticals (REGN) Cash from Financing Activities (2009 - 2026)

Regeneron Pharmaceuticals' Cash from Financing Activities history runs 18 years deep, the most recent figure standing at -$802.2 million for Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 26.35% year-over-year to -$802.2 million in Q1 2026; TTM through Mar 2026 was -$3.4 billion, a 2.75% decrease from a year earlier, with the FY2025 full-year figure at -$3.7 billion, down 68.84% from the prior year.
• Cash from Financing Activities eased to -$802.2 million in Q1 2026 per REGN's latest filing, from -$780.1 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $64.7 million in Q1 2022 and bottomed at -$1.1 billion in Q4 2024.
• The 5-year median for Cash from Financing Activities is -$614.2 million (2023), against an average of -$559.8 million.
• Across the five-year window, Cash from Financing Activities soared 117.66% in 2022 and sank 2412.53% in 2025, its largest moves.
• Year by year, Cash from Financing Activities stood at -$247.6 million in 2022, then tumbled by 80.17% to -$446.1 million in 2023, then tumbled by 154.54% to -$1.1 billion in 2024, then soared by 31.3% to -$780.1 million in 2025, then fell by 2.83% to -$802.2 million in 2026.
• Per Business Quant, the three latest REGN Cash from Financing Activities figures stand at -$802.2 million (Q1 2026), -$780.1 million (Q4 2025), and -$717.9 million (Q3 2025).